The Global Acute Repetitive Seizures Market Size accounted for USD 569 Million in 2021 and is estimated to achieve a market size of USD 16,753 Million by 2030 growing at a CAGR of 45.9% from 2022 to 2030. The development of new routes of administration for epileptic seizures, newer pharmacological therapies, and hereditary factors connected to brain abnormalities and epileptic seizures are a few of the primary reasons driving the global acute repeated seizures market value. Furthermore, significant unmet clinical needs for caregivers and patients as well as the availability of cutting-edge product pipelines, are anticipated to drive acute repetitive seizures market growth in the coming years.

Acute Repetitive Seizures Market Report Key Highlights

• Global acute repetitive seizures market revenue is estimated to expand by USD 16,753 Million by 2030, with a 45.9% CAGR from 2022 to 2030.
• North America acute repetitive seizures market share accounted for over 36% of total shares in 2021
• Asia-Pacific acute repetitive seizures market growth will observe fastest CAGR from 2022 to 2030
• Based on product, diastat rectal gel segment accounted for over 34% of the overall market share in 2021
• UCB S.A. and Neurelis, Inc. are expected to hold the significant share of the global market in 2021
• High demand for nasal sprays for the epilepsy treatment, drives the acute repetitive seizures market size

Acute repetitive seizures (ARS) are known as recurrent, serial, or cluster seizures. It is a phenomenon in treatment-refractory epilepsy that is distinguished by a close chronological connection of seizures that surpass a patient’s typical baseline seizure occurrence. ARS poses a risk of hospitalization and/or evolution into status epilepticus, a life-threatening seizure emergency, which underscores the need for early, effective management. Benzodiazepines are usually used as needed for rescue treatment in this orphan indication, being prescribed adjunctively to patients’ chronic antiepileptic drug (AED) regimen and administered on an as-needed basis.

Global Acute Repetitive Seizures Market Trends

Market Drivers

• Increasing focus on the introduction of new medications
• High demand for nasal sprays for the epilepsy treatment
• Significant growth in the number of clinical studies

Market Restraints

• Lack of knowledge of seizures
• Adverse reactions caused due to drugs, drug-induced seizures

Market Opportunities

• Growing number of supervisory authorizations
• Promising treatment options in the pipeline

Acute Repetitive Seizures Market Report Coverage

The growth of this market is highly attractive including the growing prevalence of neurological diseases and strong pipeline products and the increasing number of regulatory approval. Moreover, growing investment in research and development is expected to offer dynamic growth opportunities as major branded drugs are in the pipeline phase and are likely to be introduced in the market very soon with help of robust research and development projects. Shifting the consumer base from the rectal to the nasal route of administration is anticipated to offer growth opportunities. However, lack of awareness of seizures is one of the major treatment challenges in some of the countries of Asia-Pacific including India. This problem is further exaggerated due to poor accessibility of adequate health care provision, lack of affordable treatment, availability of specialist care, distance to health care facilities, and obtainability of pharmacological treatment. Moreover, the population in such countries is unaware of new treatments for neurological disorders.

On the other hand, an increase in the demand for safe alternative and cost-effective alternatives has led to the emergence of clinical studies for evaluating the safety and effectiveness of nasal route administration in the form of nasal sprays.

Acute Repetitive Seizures Market Segmentation

The worldwide acute repetitive seizures market segmentation is based on the product, and geography.

Acute Repetitive Seizures Market By Product

• USL-261
• NRL-1
• Diastat Rectal Gel
• AZ-002
• Others

According to the acute repetitive seizures industry analysis, the diastat rectal gel segment can hold a significant market share in 2021. This growth is owing to its expertise and the lack of FDA-approved medications on the market. It is the only FDA-approved medicine, and generic versions were introduced in 2010. Patients prefer the intra-nasal method over other types of pharmaceutical administration routes such as buccal, rectal, as well as intramuscular. Parenteral medicines have been proven to be the best option for outpatient therapy.

Acute Repetitive Seizures Market Regional Outlook